ALKEM LABORATORIES
|
ALKEM LABORATORIES Last 5 Year Financial Ratios History
[Consolidated]
| Mar2023 | Mar2022 | Mar2021 | Mar2020 | Mar2019 | |
|---|---|---|---|---|---|
| Operational & Financial Ratios | |||||
| Earnings Per Share (Rs) | 82.32 | 137.65 | 132.58 | 94.28 | 63.61 |
| CEPS(Rs) | 110.18 | 165.98 | 158.29 | 117.28 | 80.87 |
| DPS(Rs) | 50.00 | 34.00 | 30.00 | 25.00 | 16.00 |
| Book NAV/Share(Rs) | 756.56 | 722.48 | 616.95 | 515.21 | 454.86 |
| Tax Rate(%) | 22.84 | 8.89 | 12.18 | 8.77 | 18.96 |
| Margin Ratios | |||||
| Core EBITDA Margin(%) | 8.97 | 13.44 | 14.82 | 11.89 | 10.41 |
| EBIT Margin(%) | 7.87 | 12.42 | 14.50 | 10.69 | 9.42 |
| Pre Tax Margin(%) | 7.27 | 12.07 | 14.05 | 10.16 | 8.91 |
| PAT Margin (%) | 5.61 | 11.00 | 12.34 | 9.27 | 7.22 |
| Cash Profit Margin (%) | 7.34 | 12.99 | 14.43 | 11.31 | 9.03 |
| Performance Ratios | |||||
| ROA(%) | 7.99 | 14.50 | 16.66 | 13.92 | 10.66 |
| ROE(%) | 11.39 | 20.99 | 23.91 | 19.82 | 15.02 |
| ROCE(%) | 13.09 | 18.69 | 22.56 | 18.71 | 16.49 |
| Asset Turnover(x) | 1.42 | 1.32 | 1.35 | 1.50 | 1.48 |
| Sales/Fixed Asset(x) | 4.36 | 3.84 | 3.56 | 3.74 | 3.80 |
| Working Capital/Sales(x) | 3.66 | 4.21 | 3.95 | 5.48 | 5.39 |
| Efficiency Ratios | |||||
| Fixed Capital/Sales(x) | 0.23 | 0.26 | 0.28 | 0.27 | 0.26 |
| Receivable days | 40.86 | 41.72 | 45.33 | 42.66 | 39.69 |
| Inventory Days | 57.10 | 63.54 | 57.51 | 48.86 | 50.14 |
| Payable days | 97.40 | 114.79 | 118.18 | 118.18 | 135.69 |
| Valuation Parameters | |||||
| PER(x) | 41.27 | 26.28 | 20.91 | 24.70 | 27.54 |
| PCE(x) | 30.84 | 21.79 | 17.51 | 19.86 | 21.66 |
| Price/Book(x) | 4.49 | 5.01 | 4.49 | 4.52 | 3.85 |
| Yield(%) | 1.47 | 0.94 | 1.08 | 1.07 | 0.91 |
| EV/Net Sales(x) | 3.39 | 4.07 | 3.71 | 3.40 | 2.88 |
| EV/Core EBITDA(x) | 21.53 | 19.52 | 15.10 | 17.98 | 17.65 |
| EV/EBIT(x) | 27.84 | 22.80 | 17.28 | 21.41 | 21.03 |
| EV/CE(x) | 3.16 | 3.39 | 3.16 | 3.15 | 2.83 |
| M Cap / Sales | 3.50 | 4.07 | 3.74 | 3.34 | 2.85 |
| Growth Ratio | |||||
| Net Sales Growth(%) | 9.08 | 19.96 | 6.24 | 13.42 | 15.10 |
| Core EBITDA Growth(%) | -17.60 | 1.84 | 37.90 | 31.20 | 6.95 |
| EBIT Growth(%) | -25.55 | -0.23 | 43.49 | 31.27 | 2.85 |
| PAT Growth(%) | -40.08 | 3.87 | 40.76 | 48.56 | 21.18 |
| EPS Growth(%) | -40.19 | 3.82 | 40.63 | 48.20 | 20.54 |
| Financial Stability Ratios | |||||
| Total Debt/Equity(x) | 0.14 | 0.30 | 0.23 | 0.26 | 0.17 |
| Current Ratio(x) | 2.32 | 1.76 | 1.92 | 1.70 | 1.90 |
| Quick Ratio(x) | 1.62 | 1.13 | 1.28 | 1.14 | 1.22 |
| Interest Cover(x) | 13.15 | 36.22 | 32.26 | 20.36 | 18.48 |
| Total Debt/Mcap(x) | 0.03 | 0.06 | 0.05 | 0.06 | 0.05 |
Compare Financial Ratios of peers of ALKEM LABORATORIES
| Peers & Returns | Market Capitalization | 1 Week | 1 Month | 1 Year | ||
| ALKEM LABORATORIES | ₹56,622.2 Cr | 2.8% | -7.7% | 54.1% | Stock Analytics | |
| SUN PHARMACEUTICAL INDUSTRIES | ₹368,766.0 Cr | 3% | 2.3% | 68.2% | Stock Analytics | |
| CIPLA | ₹111,102.0 Cr | 2.5% | 0.4% | 71.7% | Stock Analytics | |
| DR REDDYS LABORATORIES | ₹100,958.0 Cr | -0.2% | -4.9% | 40.3% | Stock Analytics | |
| DIVIS LABORATORIES | ₹99,939.6 Cr | -1.6% | -7% | 23.8% | Stock Analytics | |
| ZYDUS LIFESCIENCES | ₹95,104.2 Cr | 5% | 10.4% | 109.1% | Stock Analytics | |
ALKEM LABORATORIES Share Price vs Sensex
| Share Price Returns(%) | 1 Week | 1 Month | 1 Year |
| ALKEM LABORATORIES | 2.8% |
-7.7% |
54.1% |
| SENSEX | -2.4% |
-1% |
21.3% |
You may also like the below Video Courses
